RxDoctor Payments Data

Xin Zhang, MD

Internal Medicine · Riverside, CANPI 1528043551

Payments from drug & device makers

$3,685in general payments, 2019–2025

Across 98 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AstraZeneca$563
  • Abbott$313
  • Novo Nordisk$283
  • Amgen$157
  • Lilly USA, LLC$135
  • plus $495 from 13 others

What the payments were for

  • Grants$90124%
  • Travel & lodging$68819%
  • Food & beverage$2,09657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,685 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$43,733
Medicare patients
100
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate88$69,514
EliquisApixaban81$66,156
OzempicSemaglutide62$65,990
XareltoRivaroxaban48$44,841
FarxigaDapagliflozin Propanediol51$40,378
JardianceEmpagliflozin30$31,352
MounjaroTirzepatide31$30,116
TrulicityDulaglutide23$23,665
RybelsusSemaglutide12$13,240
Xigduo XrDapaglifloz Propaned/Metformin12$8,499
Atorvastatin Calcium605$6,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$5,923
Levothyroxine Sodium335$5,668
Losartan Potassium395$5,007
Amlodipine-AtorvastatinAmlodipine/Atorvastatin21$4,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$283$79,23074 claims
MerckJanuvia$15$69,51488 claims
PfizerEliquis$21$66,15681 claims
Lilly USA, LLCMounjaro, Trulicity$135$53,78054 claims
AstraZenecaFarxiga$563$40,37851 claims
AbbVieCreon$63$1,93311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →